Entrada Therapeutics, Inc.
The company is developing endosomal escape vehicle (EEV) therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and type 1 muscular dystrophy (DM1). The company is developing EEV therapeutics designed to target intracellular targets that have previously been inaccessible and untreatable. The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 160 |
Founded | 2016 |
Financials | |
|---|---|
Market Capitalization | 636.71M |
Revenue | 162.87M |
Operating Income | 23.73M |
Operating Margin | 14.57% |
Net Income | 23.48M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 2416 / 5373 |
Sector : Healthcare | 165 / 1144 |
Industry : Biotechnology | 25 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2788 / 5565 |
Sector : Healthcare | 387 / 1182 |
Industry : Biotechnology | 172 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 2165 / 5436 |
Sector : Healthcare | 147 / 1164 |
Industry : Biotechnology | 26 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3697 / 5330 |
Sector : Healthcare | 509 / 1174 |
Industry : Biotechnology | 171 / 667 |